Intralesional immunotherapy has been effectively used in the treatment of warts; however, comparative studies between different antigens are limited.
Objective
To evaluate the efficacy and safety of intralesional measles, mumps, and rubella (MMR) vaccine compared with intralesional Candida antigen for the treatment of multiple common and plantar warts.
Methods
Sixty-eight adult patients with multiple common and plantar warts were randomly assigned into two groups, each containing 34 patients. The first group received intralesional MMR vaccine, while the second group received intralesional Candida antigen. Each treatment was injected into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions.
Results
The overall therapeutic response was higher in the Candida antigen group (73.5%) compared with the MMR group (67.7%); however, the difference was not statistically significant. Complete clearance of common warts was higher in the Candida antigen group, while that of plantar warts was higher in the MMR group. Adverse effects were transient and well tolerated in both groups. No recurrence was detected during the 6-month follow-up period.
Conclusion
Intralesional MMR and intralesional Candida antigen showed comparable efficacy and safety in the treatment of common and plantar warts.
SalmanS.AhmedMS.IbrahimAMet al. Intralesional immunotherapy for the treatment of warts: a network meta-analysis. J Am Acad Dermatol. 2019;80(4):922-930.doi:10.1016/j.jaad.2018.07.00330003983
2.
RiveraA.TyringSK. Therapy of cutaneous human papillomavirus infections. Dermatol Ther. 2004;17(6):441-448.doi:10.1111/j.1396-0296.2004.04047.x15571494
3.
FathyG.ShararaMA.KhafagyAH. Intralesional vitamin D3 versus Candida antigen immunotherapy in the treatment of multiple recalcitrant plantar warts: a comparative case-control study. Dermatol Ther. 2019;32(5):e12997.doi:10.1111/dth.1299731225688
4.
PhillipsRC.RuhlTS.PfenningerJL.GarberMR. Treatment of warts with Candida antigen injection. Arch Dermatol. 2000;136(10):1274-1275.doi:10.1001/archderm.136.10.1274-a11030787
5.
LipkeMM. An armamentarium of wart treatments. Clin Med Res. 2006;4:273-293.doi:10.3121/cmr.4.4.27317210977
6.
Kuykendall-IvyTD.JohnsonSM. Evidence-based review of management of nongenital cutaneous warts. Cutis. 2003;71(3):213-222.
7.
SterlingJCHandfield-JonesSHudsonPMBritish Association of Dermatologists. Guidelines for the management of cutaneous warts. Br J Dermatol. 2001;144(1):4-11.doi:10.1046/j.1365-2133.2001.04066.x11167676
8.
ColemanN.BirleyHD.RentonAMet al. Immunological events in regressing genital warts. Am J Clin Pathol. 1994;102(6):768-774.doi:10.1093/ajcp/102.6.7687801889
9.
HornTD.JohnsonSM.HelmRM.RobersonPK. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol. 2005;141(5):589-594.doi:10.1001/archderm.141.5.58915897380
10.
AldahanAS.MlackerS.ShahVVet al. Efficacy of intralesional immunotherapy for the treatment of warts: a review of the literature. Dermatol Ther. 2016;29(3):197-207.doi:10.1111/dth.1235226991521
11.
RajashekarTS.AmulyaR.SathishS.KumarS. Comparative study of intralesional BCG and PPD in the treatment of multiple cutaneous warts. Indian J Clin Exp Dermatol. 2018;4(1):1-6.
12.
ShaheenMA.SalemSAM.FouadDA.El-FatahAAA. Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: a comparative clinical and immunological study. Dermatol Ther. 2015;28(4):194-200.doi:10.1111/dth.1223025847793
13.
ChandraS.SilA.DattaA.PalS.DasNK. A double-blind, randomized controlled trial to compare the effectiveness and safety of purified protein derivative of tuberculin antigen with Mycobacterium w vaccine in the treatment of multiple viral warts. Indian J Dermatol Venereol Leprol. 2019;85(4):355-366.doi:10.4103/ijdvl.IJDVL_549_1831172979
14.
PodderI.BhattacharyaS.MishraVet al. Immunotherapy in viral warts with intradermal Bacillus Calmette-Guerin vaccine versus intradermal tuberculin purified protein derivative: a double-blind, randomized controlled trial comparing effectiveness and safety in a tertiary care center in Eastern India. Indian J Dermatol Venereol Leprol. 2017;83(3):411.doi:10.4103/0378-6323.19362327852999
15.
MunnangiP. Comparative study between intralesional MMR and intralesional BCG in treatment of verruca vulgaris. IOSR J Dent Med Sci. 2018;17:44-50.
16.
NofalA.SolimanM.HamdyF.AlakadR. Intralesional Candida antigen versus intralesional tuberculin in the treatment of recalcitrant genital warts: a comparative study. J Am Acad Dermatol. 2020;82(6):1512-1514.doi:10.1016/j.jaad.2019.12.05031923442
17.
NofalA.YehiaE.KhaterE.BessarH. Alternating intralesional purified protein derivative and Candida antigen versus either agent alone in the treatment of multiple common warts. J Am Acad Dermatol. 2020;83(1):208-210.doi:10.1016/j.jaad.2020.01.05432006600
18.
NaCH.ChoiH.SongSH.KimMS.ShinBS. Two-year experience of using the measles, mumps and rubella vaccine as intralesional immunotherapy for warts. Clin Exp Dermatol. 2014;39(5):583-589.doi:10.1111/ced.1236924934912
19.
DhopeA.MadkeB.SinghA. Effect of measles mumps rubella vaccine in treatment of common warts. Indian J Drugs Dermatol. 2017;3(1):14-19.doi:10.4103/ijdd.ijdd_1_17
20.
Abd El-MagiudEM.Abd El-SameaGM.GaberHD. Intralesional injection of measles, mumps, and rubella vaccine versus cryotherapy in treatment of warts: a randomized controlled trial. Dermatol Ther. 2020;33(2):e13257.doi:10.1111/dth.1325732031726
21.
NofalA.NofalE. Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol. 2010;24(10):1166-1170.doi:10.1111/j.1468-3083.2010.03611.x20202055
22.
ChauhanPS.MahajanVK.MehtaKS.RawatR.SharmaV. The efficacy and safety of intralesional immunotherapy with measles, mumps, rubella virus vaccine for the treatment of common warts in adults. Indian Dermatol Online J. 2019;10(1):19-26.doi:10.4103/idoj.IDOJ_142_1830775294
23.
KimKH.HornTD.PharisJet al. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol. 2010;146(12):1431-1433.doi:10.1001/archdermatol.2010.35021173332
24.
MaronnM.SalmC.LyonV.GalbraithS. One-year experience with Candida antigen immunotherapy for warts and molluscum. Pediatr Dermatol. 2008;25(2):189-192.doi:10.1111/j.1525-1470.2008.00630.x18429776
25.
AttwaE.ElawadyR.SalahE. ‘Cryo-immuno-therapy’ is superior to intralesional Candida antigen monotherapy in the treatment of multiple common warts. J Dermatolog Treat. 2020;3:1-8.doi:10.1080/09546634.2020.172058532009473
26.
NofalA.SalahE.NofalE.YosefA. Intralesional antigen immunotherapy for the treatment of warts: current concepts and future prospects. Am J Clin Dermatol. 2013;14(4):253-260.doi:10.1007/s40257-013-0018-823813361
27.
KingM.JohnsonSM.HornTD. Intralesional immunotherapy for genital warts. Arch Dermatol. 2005;141(12):1606-1607.doi:10.1001/archderm.141.12.160616365274
28.
GuptaS.MalhotraAK.VermaKK.SharmaVK. Intralesional immunotherapy with killed Mycobacterium W vaccine for the treatment of ano-genital warts: an open label pilot study. J Eur Acad Dermatol Venereol. 2008;22(9):1089-1093.doi:10.1111/j.1468-3083.2008.02719.x18484970
29.
CliftonMM.JohnsonSM.RobersonPK.KincannonJ.HornTD. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol. 2003;20(3):268-271.doi:10.1046/j.1525-1470.2003.20318.x12787281
30.
SignoreRJ. Candida albicans intralesional injection immunotherapy of warts. Cutis. 2002;70(3):185-192.
JohnsonSM.RobersonPK.HornTD. Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol. 2001;137(4):451-455.11295925
